Brussels IVF, the center for reproductive medicine at UZ Brussel, has a strong commitment to scientific research alongside clinical practice. Since its inception in 1983, research has been an essential part of the center's DNA, contributing to its pioneering role in reproductive technologies.
Research Areas and Focus
Brussels IVF conducts research across all fields of reproductive medicine, including:
- Basic research into embryonic development
- Clinical studies on stimulation protocols
- Investigations to improve oocyte and embryo quality
- Improving clinical outcomes
- Research to enhance patient comfort during treatment
- Implementation of artificial intelligence and automation in existing ART techniques
This research has contributed to significant breakthroughs in fertility medicine, often in partnership with the other departments of UZ Brussel.
Research Governance and Ethics
All scientific research at Brussels IVF must receive approval from:
- The Commission for Medical Ethics of UZ Brussel
- The Federal Commission for Medical and Scientific Research on Embryos in vitro (for embryo research only)
These approvals ensure that studies meet quality criteria, reporting requirements, and patient data protection guidelines.
Research Collaborations
Brussels IVF actively participates in national and international research networks:
- Collaboration with other departments of UZ Brussel, e.g. the Centre for Medical Genetics (CMG), Gynaecology, and Diabetology
- Partnerships with research groups at VUB (REGE, REIM, FOBI, BITE)
- International cooperation with universities abroad
- Work with pharmaceutical companies
- The center is also a co-founder and active member of ESHRE (European Society of Human Reproduction and Embryology).
Patient Involvement in Research
Prospective research at Brussels IVF is only possible with explicit patient consent. Patients may be invited to participate in studies if their situation meets specific criteria, with guidance provided by specialists throughout the process. The center uses reproductive material (oocytes, sperm, embryos) that is either unsuitable for treatment or has passed the legal storage period, always with prior patient consent. Through this combination of clinical excellence and scientific research, Brussels IVF has achieved impressive results, with more than 48,000 babies born following treatments at the center.
